(Q38941557)

7 September 2017

1 reference

title

Current and experimental treatments of Parkinson disease: A guide for neuroscientists (English)

1 reference

7 September 2017

1 reference

1

Wolfgang Oertel

1 reference

7 September 2017

2

Jörg B Schulz

1 reference

7 September 2017

language of work or name

English

0 references

publication date

30 August 2016

1 reference

Journal of Neurochemistry

7 September 2017

published in

1 reference

7 September 2017

volume

139 Suppl 1

1 reference

7 September 2017

page(s)

325-337

1 reference

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

7 September 2017

cites work

1 reference

Parkinson's disease protects against smoking?

21 January 2018

1 reference

Are synucleinopathies prion-like disorders?

21 January 2018

1 reference

Urate as a predictor of the rate of clinical decline in Parkinson disease

21 January 2018

1 reference

MDS research criteria for prodromal Parkinson's disease

21 January 2018

1 reference

Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease

21 January 2018

1 reference

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

21 January 2018

1 reference

Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin

21 January 2018

1 reference

A randomized trial of deep-brain stimulation for Parkinson's disease

21 January 2018

1 reference

Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study

21 January 2018

1 reference

Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease.

21 January 2018

1 reference

Cutaneous neuropathy in Parkinson's disease: a window into brain pathology

21 January 2018

1 reference

Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease

21 January 2018

1 reference

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

21 January 2018

1 reference

100 years of Lewy pathology

21 January 2018

1 reference

Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway

21 January 2018

1 reference

Smoking and Parkinson's disease: a dose-response relationship

21 January 2018

1 reference

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

21 January 2018

1 reference

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

21 January 2018

1 reference

Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?

21 January 2018

1 reference

Activity enhances dopaminergic long-duration response in Parkinson disease

21 January 2018

1 reference

Disease-modifying strategies for Parkinson's disease

21 January 2018

1 reference

Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models

21 January 2018

1 reference

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial

21 January 2018

1 reference

Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease

21 January 2018

1 reference

The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.

21 January 2018

1 reference

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice

21 January 2018

1 reference

Mortality in Parkinson's disease: a systematic review and meta-analysis

21 January 2018

1 reference

Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study

21 January 2018

1 reference

Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation

21 January 2018

1 reference

PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling

21 January 2018

1 reference

Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?

21 January 2018

1 reference

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

21 January 2018

1 reference

Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial

21 January 2018

1 reference

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

21 January 2018

1 reference

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

21 January 2018

1 reference

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

21 January 2018

1 reference

When a Parkinson's disease patient starts to hallucinate

21 January 2018

1 reference

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

Caffeine for treatment of Parkinson disease: a randomized controlled trial

21 January 2018

1 reference

Smoking, nicotine and Parkinson's disease

21 January 2018

1 reference

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

21 January 2018

1 reference

Nicotine and Parkinson's disease: implications for therapy

21 January 2018

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

21 January 2018

1 reference

Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease

21 January 2018

1 reference

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

21 January 2018

1 reference

Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients

21 January 2018

1 reference

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

Smoking and Parkinson's disease in twins.

21 January 2018

1 reference

Nicotine modulates dopamine synthesis rate as determined by L-[beta-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain

21 January 2018

1 reference

Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.

21 January 2018

1 reference

Chronic high dose transdermal nicotine in Parkinson's disease: an open trial

21 January 2018

1 reference

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease

21 January 2018

1 reference

Plasma urate and risk of Parkinson's disease

21 January 2018

1 reference

Caffeine consumption and risk of dyskinesia in CALM-PD.

21 January 2018

1 reference

Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity

21 January 2018

1 reference

Serum uric acid levels and the risk of Parkinson disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JNC.13750

1 reference

7 September 2017

1 reference